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Inhibitory selectivity among class I HDACs has a major impact on 
inflammatory gene expression in macrophages  
 
Fangyuan Cao, Martijn Zwinderman, Ronald van Merkerk, Petra Ettema, Wim Quax, Frank J. Dekker* 
Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of 
Groningen, Groningen 9713 AV, The Netherlands. 
Abstract: Histone deacetylases (HDACs) play an important role in cancer, degenerative 
diseases and inflammation. The currently applied HDAC inhibitors in the clinic lack 
selectivity among HDAC isoforms, which limits their application for novel indications such 
as inflammatory diseases. Recent, literature indicates that HDAC 3 plays an important role 
among class I HDACs in gene expression in inflammation. In this perspective, the 
development and understanding of inhibitory selectivity among HDACs 1, 2 and 3 and their 
respective influence on gene expression need to be characterized to facilitate drug discovery. 
Towards this aim, we synthesized nine structural analogs of the class I HDAC inhibitor 
Entinostat and investigated their selectivity profile among HDACs 1, 2 and 3. We found that 
we can explain the observed structure activity relationships by small structural and 
conformational differences between HDAC 1 and HDAC 3 in the ‘lid’ interacting region. 
Cell-based studies indicated, however, that application of inhibitors with improved HDAC 3 
selectivity did not provide an anti-inflammatory response in contrast to expectations from 
biochemical evidence in literature. Altogether, in this study, we identified structure activity 
relationships among class I HDACs and we connected isoform selectivity among class I 
HDACs with pro- and anti-inflammatory gene transcription in macrophages.  
Keywords  Histone deacetylases inhibitors (HDACi), Entinostat, NF-κB activity, 
inflammation. 
1. Introduction 
Histone deacetylases (HDACs) play an important rolein cancer, degenerative diseases and 
inflammation. Currently, HDAC inhibitors are in clinical use for the treatment of cancer. 
However, they often lack selectivity among HDAC isoforms, which limits their application 
for novel indications such as inflammatory diseases. Recent literature indicates that HDAC 3 













reviewed [1]). In this perspective, the development and understanding of inhibitory selectivity 
among HDACs 1, 2 and 3 and their respective influence on gene expression need to be 
characterized to facilitate drug discovery. 
HDACs are a family of enzymes that deacetylate lysine residues of histones and non-
histone proteins. Deacetylation of lysine residues in histones leads to a more condensed 
chromatin structure and makes DNA less accessible for gene transcription [2]. To date, 
eighteen HDAC isoenzymes have been identified, and they are divided into four classes based 
on their structural similarity [3,4]. Class I HDACs, which include zinc-dependent HDAC 1, 2, 
3 and 8, are well-known for their importance in gene xpression, survival, and proliferation in 
cells [5]. Therefore, small molecule inhibitors of class I HDACs have been considered as 
potential therapeutics in cancer [6], neurological disorders [7], inflammatory diseases [8] and 
also cardiac and pulmonary diseases [4]. Most of the currently available HDAC inhibitors 
share the same structural characteristics i.e. they contain: 1) a zinc-binding group (ZBG) to 
bind the zinc ion of the active site of class I HDACs, 2) a linker part that mimics the lysine 
side chain and 3) a cap group that binds to the edg of active site. In our study, we selected 
Entinostat as a class I selective HDAC inhibitor to explore structure activity relationships for 
selectivity among class I HDAC isoforms and its respective influence on pro- and anti-
inflammatory gene expression in macrophages. 
 
Figure 1. Chemical structures of HDAC inhibitors with an o-aminoanilide core structure 
Entinostat, Mocetinostat and Chidamide. The general design of HDAC inhibitors with a zinc 
binding group (blue), a linker (pink) and a cap (red) is shown. 
It has been shown that HDACs are important regulators in immune responses [9,10]. 
Therefore, development of HDAC inhibitors as new immunomodulatory therapeutics holds 













Interestingly, there are currently several clinical trials ongoing that aim to evaluate the 
synergy for combination of HDAC inhibitors and immune therapies in cancer [12,13]. 
Increasing evidence indicates that HDAC inhibitors play key roles in regulation of the 
immune cells in their respective microenvironment in immune reactions [13,14]. Key players 
in the immune microenvironment are macrophages, which can secrete both pro-inflammatory 
cytokines such as Tumor Necrosis Factor-α (TNF-α) and anti-inflammatory cytokines such as 
Interleukin-10 (IL-10) [15,16].  
In the context of airway inflammation, our previous works demonstrates that the class I 
HDAC inhibitor Entinostat has anti-inflammatory effcts upon cigarette smoke exposure in 
vivo in a mouse model. The anti-inflammatory effect observed in mice could mechanistically 
be explained by in vitro studies in Lipopolysaccharides (LPS) / Interferon γ (INFγ) - 
stimulated murine RAW 264.7 macrophages. Upon Entinos at treatment increased acetylation 
of the nuclear factor-κB (NF-κB) transcription factor, increased nuclear localization and 
increased binding to the IL-10 promotor region. This provides a mechanistic explanation of 
the observed upregulation of IL-10 expression, which is an anti-inflammatory cytokine [8]. 
Nevertheless, in the murine macrophage model we found upregulation of the expression of 
both pro- and anti-inflammatory genes [8], which indicates a mixed effect in vitro. The 
observed effects on the expression of both pro- and anti-inflammatory genes by the class I 
HDAC inhibitor Entinostat call for further investigation of the role of HDAC inhibitor 
selectivity in the regulation of pro- and anti-inflammatory gene expression. 
Here, we synthesized several analogues of Entinostat and investigated the selectivity profile 
of these analogues among class I HDACs 1, 2 and 3 and their effects on pro- and anti-
inflammatory gene expression. Structure activity relationship (SAR) for small structural 
variations in the area between the linker and the lid region of the inhibitor were investigated. 
Subsequently, the influence of HDAC inhibitor selectivity on inflammatory gene expression 
was assessed using LPS/INFγ-stimulated murine macrophages. 
2. Results and discussion 
2.1 Synthesis 
The synthetic routes to obtain the desired compounds are outlined in Scheme 1, 2 and 3. 
The o-aminoanilide derivatives 4a, 4b and 4d were prepared in two steps (Scheme 1). A 
reductive amination reaction was used to obtain 3 , 3b and 3d with yields between 45%-75%. 













reaction using EDCI and HOBt as reagents in a yield of 81%, followed by hydrolysis of the 
ester using lithium hydroxide to obtain compound 4c in a yield of 54%. Compounds 4a-d 
were obtained by a condensation reaction from 3a-d with o-phenylenediamine using EDCI 
and HOBt as reagents in a yield of 30%-61%.  
 
Scheme 1. Reagents and conditions: a) EDCI, HOBt, CH2 l2, Et3N,r.t. overnight; b) LiOH, 
CH2Cl2, r.t., 3 h; c) 50 
oC, 6 h; NaBH3CN, methanol, r.t. , overnight; d) o-phenylenediamine, 
EDCI, HOBt, DCM, Et3N, r.t. overnight. 
The pure enantiomers of 4b were prepared in four steps starting from commercially 
available (R)-(+)- or (S)-(-)-1-(4-bromophenyl)ethylamine and iodobenzene (Scheme 2). The 
first step was done by an Ullmann reaction to couple 1-(4-bromophenyl)ethylamine and 
iodobenzene using L-proline and CuI to give 7a and 7b with yields around 33%. Compounds 
7a and 7b were subjected to cyanation using zinc cyanide with 
tetrakis(triphenylphosphine)palladium(0) as catalyst to obtain 8a and 8b with a yield of about 
57%. The cyanides 8a and 8b were hydrolyzed and coupled with o-phenylenediamine to 


















, L-Proline, CuI, DMSO, 80 
o







, DMF, 105 
o
C, overnight; c) 12 N HCL, 100 
o
C, overnight; d) EDCI, 
HOBt, CH2Cl2, r.t., overnight. 
Compounds 15a-c were obtained in two or three steps (Scheme 3). Compound 12a was 
produced by using an Ullmann reaction in which 6-aminohexanoic acid and phenyliodide 
were coupled using deanol and CuI in alkaline conditions [17]. Carboxylates 12a-c were 
coupled with N-Boc-1,2-phenylenediamnie to give the Boc protected 14a-c with low to 
moderate yields (6-66%). Boc deprotection was achieved by trifluoroacetic acid treatment to 
obtain the final product 15a-c. 
 








C, overnight; b) EDCI, 
HOBt, CH2Cl2, r.t. overnight; c)  TFA, CH2Cl2, r.t. 2h. 
2.2 HDAC inhibition  
The resulting collection of HDAC inhibitors was test d for HDAC inhibition using 
procedures to assay HDAC activity as described previously by us [18] and others. The IC50 
values of HDAC inhibitors for HDAC 1, 2 and 3 are listed in Table 1, 2 and 3. In line with 
prior reports, Entinostat provided IC50’s in the nM range [8,19]. The structure activity 
relationships show that replacement of the ‘lid’ region of Entinostat by a phenyl, as present in 
4a, results in a loss of potency for HDAC 1 and 2, whereas the HDAC 3 inhibition remains 
similar. Using the compound collection 4a, 4b, 4c and 4d, we probed the selectivity profile 
among HDACs 1, 2 and 3 (Table 1) by variation of the benzylic position between the ‘linker’ 
and the ‘lid’ region. We observed that introduction f a methyl or a carbonyl in the benzylic 
position provides inhibitors 4b and 4c with respectively 10- or 20-fold reduced inhibitory 
potency for HDAC 3 compared to much smaller changes for HDAC 1 and 2. Introduction of a 
methyl on the benzylamine nitrogen in 4d provides much smaller changes in affinity. The two













S-(-)enantiomer 10a and R-(+)-enantiomer 10b are displaying the same selective profile 
among HDACs 1, 2 and 3, but R-(+)-enantiomer 10b shows 2 times better inhibitory potency . 
Table1. IC50 values of Entinostat and 4a-d for HDAC 1, HDAC 2 and HDAC 3. Data are 
presented as mean values (in µM) ± SD.





0.19±0.04 0.41±0.09 0.95±0.19 
4a 
 
1.0±0.1 1.4±0.05 0.6±0.05 
4b 
 
2,3±0.2 7.0±0.5 8,5±0.5 
10a  
 
2.4±0.6 8.3±0.8 11±0.7 
10b 
 
1.3±0.1 4,2±0.6 5.0±0.1 
4c 
 
3.0±0.4 5.4±0.3 16±2.2 
 4d 
 
1.0±0.03 0.5±0.01 2.8±0.06 
     aIC50 values for Entinostat are taken from Leus et al., 2017. 
Based on prior literature [20], we set out to explore a series of compounds 15a-c with 
HDAC 3 inhibitory selectivity (Table 2). Compound 15a shows the highest potency for 
HDAC 3, whereas 15b has equal IC50’s for HDAC 1 and 3. Compound 15c has the clearest 
selectivity profile with the highest potency for HDAC 3 in the same range as RGFP966. 
Table 2. IC50 values of RGFP966 and compound 15a-c for HDAC 1, 2 and 3. Data are 
presented as mean values. (in µM) ± SD.




         
5.6±1.3 9.7±1.8 0.21±0.06 
15a 
 















1.9±0.1 3.7±0.7 1.2±0.1 
15c 
 
4.2±0.8 8.1±1.5 0.6±0.07 
   a IC50 values for RGFP966 are taken from Leus et al., 2016. 
2.3 Docking studies 
A molecular modelling study was performed to connect the observed SAR among class I 
HDACs 1, 2 and 3 to structural information. Towards this aim a selection of the inhibitors 
was docked into the active sites of HDACs by the program Discovery studio (Dassault 
systèmes) version 2018, using the crystal structures of human HDAC 1 (PDB-code: 5ICN), 
human HDAC 2 (PDB-code: 4LY1) and human HDAC 3 (PDB-code: 4A69). The 
CDOCKER protocol was employed for docking by a CHARMm based algorithm. This 
docking protocol was verified by redocking of the ligand (4-(acetylamino)-N-[2-amino-5-
(thiophen-2-yl)phenyl]benzamide) from the HDAC 2 crystal structure [21]. The ligand was 
removed from the HDAC 2 crystal structure, and then, was docked back using the 
CDOCKER protocol. This provides positions comparable to the original binding pose in all 
top 10 lowest CDOCKER energies poses [21] , thus confirming that the docking protocol can 
recapitulate the binding pose in the crystal structure of HDAC 2. Next, we verified the 
docking protocol for HDAC 1 and 3. We made an overlay of HDAC 1, 2 and 3 on the α-
carbon atoms of the protein backbone and copied the ligand (4-(acetylamino)-N-[2-amino-5-
(thiophen-2-yl)phenyl]benzamide) from the HDAC 2 crystal structure 4YL1 into the active 
sites of HDAC 1 and 3. Subsequently, the o-aminoanilide core was used as a reference to 
evaluate the docking of the inhibitors into the HDAC 1 and 3 active sites. We found that the 
docking protocol enables positioning of o-aminoanilide core of the novel inhibitors in HDAC 
1 and 3 active site with poses that are very similar to the pose of o-aminoanilide core of the 
reference inhibitor in HDAC 2. The top 10 CDOCKER energies poses were visually 
inspected and poses in which the o-aminoanilide core docked outside the active site were 
discarded. For all the ligands a high convergence i the position of o-aminoanilide core was 
observed in the 10 highest ranked poses (examples are hown in Figure S1 and S2). Poses 
with the lowest CDOCKER energies are shown as repres ntative poses in all figures. 
Firstly, we performed a docking analysis to find an explanatio  for the 20-fold difference 
in HDAC 3 inhibitory potency between 4a and 4c (Figure 2A). The amine and carbonyl of o-













active site to chelate the zinc ion in the catalytic center. The phenyl linker moiety of both 
compounds forms π-π stacking with Phe144 and Phe 200 in HDAC 3 to fit the hydrophobic 
tunnel of the active site. Interestingly, the docking ndicates that compound 4c with the amide 
group instead of a benzylic nitrogen between the ‘linker’ and the ‘lid’ doesn’t interact in the 
‘lid’ region with the protein surface in contrast to 4a. The amide linkage is connected to a 10-
fold loss in potency for HDAC 3 and not for HDAC 1 and 2, thereby indicating that binding 
of the phenyl to the lid region is key for HDAC 3 binding in contrast to HDAC 1 and 2. 
Based on the idea that flexibility is key for HDAC 3 binding we explored a set of 
compounds with a flexible linker (Table 2). Because of its clearest preference for binding to 
HDAC 3, we focused on compound 15c. This molecule was docked in the active site of 
HDAC 1 and 3 and superimposed (Figure 2B). Using this docking we compared the position 
of the amino acids in the respective HDAC active sit s. A high degree of overlap in the amino 
acids of the HDAC 1 and HDAC 3 active sites was observed as well as in the docked 
conformation of 15c. The only exception is amino acid Asp93 in HDAC 3 compared with 
Asp99 in HDAC 1 for which the α-carbon atom as well as the amino acid side chain occupy 
alternative positions. The carboxylic acid of Asp99 in HDAC 1 is located more towards the 
outside of active site than Asp93 in HDAC 3. This positional and conformational difference 
can be attributed to the difference between Glu98 in HDAC 1 and Asp92 in HDAC 3. In the 
crystal structure, Asp99 in HDAC 1 is hydrogen bonded with three water molecules (Figure 
2C), whereas Asp93 in HDAC 3 is only hydrogen bonded to one water molecule (Figure 2D). 
This could contribute to a higher propensity for hydrogen bonding to Asp92 in HDAC 3 
compared to Asp99 in HDAC 1 thus resulting in a high affinity of compound 15c for HDAC 
3 compared to HDAC 1. Thus, the positional differenc  between Asp99 in HDAC 1 and 
Asp92 in HDAC 3 provides a structural basis to design inhibitors with selectivity among these 
HDAC isoenzymes by targeting the region between the ‘linker’ and the ‘lid’ region of the 
inhibitors. This adds to the structural understanding of inhibitor selectivity among HDAC 1, 2 













     
 
Figure 2. Docking HDAC inhibitors in the active sites of HDAC 1 and 3. A) Modelling of 4a 
and 4c in the active site of HDAC 3. 4a is colored in orange, and 4c is colored in green. The 
blue mesh indicates the active site surface of HDAC 3, with a grey-colored zinc atom. B) 
Alignment of HDAC 1 and 3 structures docked with compound 15c. HDAC 1 is labeled in 
green, and HDAC 3 is labeled in blue with a grey colored zinc atom. The distance between 
Asp99 in HDAC 1, while Asp93 in HDAC 3 and the compound is marked in light blue. C) 
Water coverage of Asp99 HDAC 1 in compound 15c modelling. D) Water coverage of Asp93 
HDAC 3 in compound 15c modelling.  
2.4 NF-κB activation 
It is known that NF-κB is an important regulator in cytokine secretion of macrophages [18] 
[26]. Our previous study has shown that Entinostat restored anti-inflammatory IL-10 
expression in LPS/INFγ-treated macrophages, which is connected to increased NF-κB p65 
transcriptional activity, acetylation, nuclear localiz tion, and binding to the IL-10 promoter 
[8]. Therefore, we aimed to connect HDAC isoenzyme selectivity to effects on NF-κB 
transcriptional activity. Inhibitors with different HDAC selectivity profiles were tested for 















cells. LPS/IFNγ-stimulated RAW-Blue cells were treated with compounds at non-toxic 
concentrations ranging between 1-5µM (data on cell viability are shown in the supporting 
information). The pan-HDAC inhibitor SAHA was used as a reference. As shown in Figure 3, 
both Entinostat and 10b upregulated the NF-κB transcriptional activity, whereas RGFP966 
and 15c did not show obvious effects on reporter gene expression at the concentrations 
applied. Both Entinostat and compound 10b have a preference for HDAC 1 inhibition 
compared to a preference for HDAC 3 for RGFP966 and15c. These results indicate that 
HDAC 1 inhibition, rather than HDAC 3 inhibition, plays an essential role in the NF-κB 
transcriptional activation in this model. 
 
Figure 3. Effect of SAHA, Entinostat, RGFP966, 10b and 15c on NF-κB transcriptional 
activity in LPS/IFNγ-stimulated RAW BLUE cells. Cells were treated with the respective 
HDAC inhibitors at the indicated concentrations for20 h and stimulated with LPS/IFNγ for 
the last 4 h of the experiment. The data shown represent means ± SD of 3 independent 
experiments. ***p<0.001 and **p<0.01 compared to vehicle treated cells.   
2.5 Gene expression  
Subsequently, we investigated the effect of HDAC inhibitors with different selectivity’s 
among HDAC 1, 2 and 3 isoenzymes on pro- and anti-inflammatory gene expression. We 
employed LPS/IFNγ-stimulated RAW264.7 cells to monitor expression of tumor necrosis 













inflammatory genes and expression of IL-10 as anti-inflammatory gene [8]. As observed 
previously, Entinostat increased the expression of both pro- and anti-inflammatory genes. 
This effect was also observed using the inhibitor 4b, which also preferably inhibits HDAC 1 
(despite at higher concentrations compared to Entinostat due to a lower inhibitory potency). 
On the contrary, inhibitors with a preference for HDAC 3 inhibition did not show significant 
effects on gene expression. These results indicate th  small molecule inhibition of HDAC 3 
may not be strongly connected with regulation of pr- and anti-inflammatory gene expression 
in this model. This in contrast to previous findings with siRNA mediated downregulation of 
HDAC 3 downregulated pro-inflammatory gene expression and upregulated expression of IL-
10 [27]. Possibly, the structural role of HDAC 3 is more important than its catalytic activity in 
regulation of pro- and anti-inflammatory gene expression. On the contrary, this study shows 
that inhibition of the catalytic activity of HDAC 1 or/and HDAC 2 is associated with 
expression of both pro-inflammatory and anti-inflammatory genes. This indicates a crucial 
role for the HDAC 1 and HDAC 2 isoforms in the function of macrophages. The stimulation 
of pro-inflammatory gene expression by HDAC 1 and/or 2 directed inhibitors indicates a role 













   
                                     
Figure 4. Effects of Entinostat, RGFP966, 15c and 10b on pro- and anti- inflammatory gene 
expression of A) IL10, B) iNOS, C) IL6 and D) TNFα in RAW264.7 macrophages. Cells were 
treated with the respective HDAC inhibitors at the indicated concentrations for 20 h and 
stimulated with LPS/IFNγ for the last 4 h of the experiments. Gene expression was analyzed 
by RT-qPCR. For vehicle treatment, cells were pre-treated with a proportional dilution of the 
inhibitor solvent DMSO. Data are shown represent as mean values ± SD of 2-3 independent 
experiments. *** p< 0.001 compared to vehicle treated cells. * p<0.05 compared to vehicle 
treated cells. 
3 Conclusion 
In this study, we set out to evaluate the structure activity relationships for selectivity 
among the HDACs 1, 2 and 3 by structural variation of the unit between the ‘linker’ and the 
‘lid’ region of o-aminoanilide type HDAC inhibitors. We found that differences in HDAC 1 
and HDAC 3 binding can be explained by a structural difference between HDAC 1 and 
HDAC 3. The Asp92 residue in HDAC 3 occupies a positi n that is different from the 













tunnel towards the catalytic site, which could provide a higher propensity for hydrogen 
bonding, which would explain the 10-fold differences in potency for HDAC 3 inhibition as 
observed in this study. Subsequently, we set out to connect class I HDAC inhibitory 
selectivity to NF-κB transcriptional activity and pro- and anti-inflammatory gene expression. 
We found that HDAC 1 and/or HDAC 2 selectivity increased the NF-κB transcriptional 
activity, whereas HDAC 3 selectivity provided no effect. The same was observed for both 
pro- and anti-inflammatory gene expression in which HDAC 1 and/or 2 selectivity 
upregulated gene expression, whereas HDAC 3 selectivity did not provide significant effects. 
The lack of effect observed with HDAC 3 selective inhibitors stand in contrast to previous 
studies employing siRNA downregulation thus indicating a structural role for HDAC 3 in 
inflammatory signaling and not a catalytic role. Altogether, this study provides a basis to 
further explore isoenzyme selective class I HDAC inhibitors in applications involving 
immune regulation such as inflammatory disorders and oncology. 
4 Experimental section 
4.1 Chemistry 
4.1.1 General 
The solvents and reagents were purchased from Sigma-Aldrich, Acros chemicals or abcr 
GmbH without further purification. Reactions were monitored by thin layer chromatography 
(TLC). Merck silica gel 60 F254 plates were used anspots were detected under UV light or 
after staining with potassium permanganate for the non UV-active compounds. MP 
Ecochrom silica 32-63, 60Å was used for flash column chromatography. 1H NMR (500 
MHz) and 13C NMR (126 MHz) spectra were recorded with a Bruker Avance 4-channel 
NMR Spectrometer with TXI probe. Chemical shifts were referenced to the residual proton 
and carbon signal of the deuterated solvent CDCl3: δ = 7.26 ppm (
1H) and 77.05 ppm (13C), 
(CD3)2SO: δ = 2.50 ppm (
1H) and 39.52 ppm (13C)，CD3OD: δ = 3.31 ppm (
1H) and 49.00 
ppm (13C). The following abbreviations were used for spin multiplicity: s = singlet, br. s = 
broad singlet, d = doublet, t = triplet, q = quartet, p = quintet, dd = double of doublets, ddd = 
double of doublet of doublets, m = multiplet. Fourier Transform Mass Spectrometry (FTMS) 
was recorded on an Orbitrap XL Hybrid Ion Trap-Orbitrap Mass Spectrometer to give high-
resolution mass spectra (HRMS).  
4.1.2 Synthetic procedure 1: Reductive Amination 
The respective substituted benzoic acid (4.0 mmol) was dissolved in MeOH (7.0 mL). The 













catalytic amount of acetic acid (10 drops) was added into the mixture. The reaction was 
stirred at 50 oC for 3 h. The mixture was then cooled to room temprature. Molecular sieves 
and NaBH3CN (12 mmol) were added and stirring was continued for 16 h. The reaction was 
quenched with water (20 mL). The suspension was filtered, and the residue was washed with 
water (20 mL, 3 times) and dried to obtain the final product. 
4.1.3 Synthetic procedure 2: Amidation Reaction 
The respective carboxylic acid derivative (2 mmol) was added into a flask with dry CH2Cl2 (5 
mL) and was put on ice. EDCI (2.4 mmol) and HOBt (0.8 mmol) were then added into the 
mixture and the reaction was stirred on ice for 15 min. Then Et3N (2.0 mmol) was added into 
the mixture, followed the amine (2.0 mmol). Subsequently, the mixture was stirred at room 
temperature overnight. The reaction mixture was evaporated under reduced pressure. The 
residue was purified by flash chromatography using Petroleum ether: EtOAc 5:1 (v/v) as 
eluent, to obtain the final product. 
4.1.4 Synthetic procedure 3: Ester hydrolysis 
Compound 3c (3.8 mmol) was dissolved in THF:MeOH (8 mL: 4 mL) and a solution of 
LiOH (15 mmol) in water (8 mL) was added. The reaction was stirred at room temperature 
for 4h until the solution became homogeneous. The reaction was acidified to pH 1.0 with an 
aqueous 1 N HCl solution. The solvents were evaporated under reduced pressure, and the 
residue was dissolved in the EtOAc:CH2Cl2 (15 mL:15 mL) and washed with water (20 mL, 
3 times). The organic layers were combined, dried over MgSO4 and evaporated to afford the 
final product. 
4.1.5 Synthetic procedure 4: Ullmann Reaction using L-proline 
A mixture of iodobenzene (5.0 mmol), (S)- or (R)-4-bromo-phenylethylamine (5.0 mmol), 
K2CO3 (10 mmol), CuI (0.50 mmol) and L-proline (1.0 mmol) in DMSO (6 mL) was heated 
to 60 °C for 20 h. After cooling, the mixture was partitioned between water and EtOAc. The 
organic layer was separated, and the aqueous layer was extracted with EtOAc (10 mL). The 
combined organic layers were washed with brine (10 mL, 3 times), dried over MgSO4, 
filtered, and concentrated under reduced pressure. Th  residual oil was purified by flash 
chromatography using Petroleum ether: EtOAc 15:1 (v/v) as eluent, to afford the product. 
4.1.6 Synthetic procedure 5: Cyanation Reaction 
The phenylbromide (1.5 mmol), ZnCN2 (3.0 mmol), and Pd[(C6H5)3P]4 (0.15 mmol) were 
dissolved in anhydrous dimethylformamide (DMF) (4 mL) under a nitrogen atmosphere. The 













temperature and an aqueous 1 N NaOH solution (10 mL) was added to quench the reaction. 
The mixture was extracted by CH2Cl2 (30 mL, 3 times). The organic layers were combined 
and washed with brine (30 mL, 3 times) and dried over MgSO4. Subsequently, the solvent 
was removed under reduced pressure to afford the crude phenylcyanide product that was 
purified by flash chromatography (Petroleum ether: EtOAc 15:1(v/v)). 
4.1.7 Synthetic procedure 6: Acidic hydrolysis of nitriles 
The phenylcyanide (0.40 mmol) was suspended in an aqueous 12 N HCl solution (3 mL) and 
heated to 100 °C overnight until the solution became homogeneous. The solvent was 
removed under reduce pressure to give the desired compound. 
4.1.8 Synthetic procedure 7: Ullmann Reaction using deanol 
A 50 mL round bottom flask was filled with iodobenze (2.0 mmol), 6-aminocaproic acid 
(3.0 mmol), CuI (0.20 mmol), K3PO4•H2O (4.0 mmol), deanol (3.0 mL) and H2O (5.0 mL). 
The atmosphere was replaced for nitrogen gas before heating to 80 oC for 48 h. After cooling 
to room temperature, ice (20 g) was added and the pH was adjusted to 4-5 using an aqueous 1 
N HCl solution. This solution was extracted with EtOAc (30 mL, 3 times). The organic layer 
was washed with brine, and the solvent was removed under reduced pressure. The residue 
was purified by flash chromatography, eluted with petroleum ether: EtOAc 1:1 (v/v), to 
obtain the desired compound. 
4.1.9 Synthetic procedure 8: Boc deprotection 
The Boc-protected amine (0.92 mmol) was dissolved in ry CH2Cl2 (6 mL). Subsequently, 
trifluoroacetic acid (TFA) (1.5 mL) was added. The mixture was stirred for 2h at room 
temperature until the solution became homogeneous. The mixture was extracted with and 
aqueous 1 N NaOH solution (20 mL). The organic layer was collected and dried over MgSO4. 
The solvent was removed under reduced pressure to obtain the final product. 
4.1.10 4-((phenylamino)methyl)benzoic acid (3a) 
The product was obtained using synthetic procedure 1. White solid, yield 53%. 1H NMR 
(500 MHz, DMSO-d6) δ 7.89 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 8.2 Hz, 2H), 7.04-7.01 (m, 2H), 
6.59 – 6.49 (m, 3H), 6.33 (br, s, 1H), 4.34 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 167.78, 
148.91, 146.11, 130.04, 129.90, 129.76, 129.32, 127.57, 127.52, 116.45, 116.28, 112.81, 
112.66, 46.67. 













 The product was obtained using synthetic procedure 1. White solid, yield 45%. 1H NMR 
(500 MHz, DMSO-d6) δ 7.86 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 6.98 – 6.94 (m, 
2H), 6.45-6.43 (m, 3H), 6.21 (d, J = 6.5 Hz, 1H), 4.52 (m, 1H), 1.41 (d, J = 6.8 Hz, 3H). 13C 
NMR (126 MHz, DMSO-d6) δ 167.26, 151.40, 147.73, 129.54, 129.42, 128.70(2), 128.67(2), 
126.05(2), 112.73(2), 51.95, 24.35. 
4.1.12 methyl 4-(phenylcarbamoyl)benzoate (2c) 
The product was obtained using synthetic procedure 2. White solid, yield 80%. 1H NMR 
(500 MHz, Chloroform-d) δ 8.17 – 8.12 (m, 2H), 7.93 (d, J = 8.3 Hz, 3H), 7.65 (d, J = 7.9 Hz, 
2H), 7.39 (t, J = 8.0 Hz, 2H), 7.18 (t, J = 7.4 Hz, 1H), 3.96 (s, 3H). 13C NMR (126 MHz, 
DMSO-d6) δ 166.15, 165.15, 139.53, 139.36, 132.46, 129.63(2), 1 9.12(2), 128.55(2), 
124.41, 120.95(2), 55.03. 
4.1.13 4-(phenylcarbamoyl)benzoic acid (3c) 
The product was obtained using synthetic procedure 1. White solid, yield 54%. 1H NMR 
(500 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.01 (d, J = 8.0 Hz, 2H), 7.91 (d, J = 8.0 Hz, 2H), 
7.82 (d, J = 7.9 Hz, 2H), 7.35 (t, J = 7.7 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H). 13C NMR (126 
MHz, DMSO-d6) δ 168.23, 165.54, 143.20, 139.21, 134.87, 128.77(2), 128.43(2), 126.63(2), 
123.39, 120.23(2). 
4.1.14 4-((methyl(phenyl)amino)methyl)benzoic acid (3d) 
The product was obtained using synthetic procedure 1. Yellow solid, yield 75%. 1H NMR 
(500 MHz, DMSO-d6) δ 12.89 (s, 1H), 7.89 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 
7.15 (t, J = 7.9 Hz, 2H), 6.70 (d, J = 8.3 Hz, 2H), 6.62 (t, J = 7.1 Hz, 1H), 4.64 (s, 2H), 3.03 
(s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 167.63, 149.35, 145.12, 130.04(2), 129.93, 
129.75(2), 129.48(2), 116.53, 112.41(2), 55.70, 39.16. 
4.1.15 N-(2-aminophenyl)-4-((phenylamino)methyl)benzamide (4a) 
The product was obtained using synthetic procedure 2. Pink solid, yield 36%. 1H NMR 
(500 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.10 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 8.1 Hz, 1H), 
7.58 (d, J = 8.1 Hz, 2H), 7.53 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.35 (t, J = 7.4 Hz, 
1H), 7.20 (t, J = 6.8 Hz, 2H), 7.02 – 6.74 (m, 3H), 4.47 (s, 2H). 13C NMR (126 MHz, DMSO-
d6) δ 165.66, 148.87, 144.65, 139.02, 133.42, 129.30(2), 1 8.29(2), 127.30(2), 127.12, 
126.90, 124.13, 117.13, 116.85, 116.33, 112.83(2), 46.57. HRMS: C20H20ON3 mass expected 













4.1.16 N-(2-aminophenyl)-4-(1-(phenylamino)ethyl)benzamide (4b) 
The product was obtained using synthetic procedure 2. Yellow solid, yield 30%.1H NMR 
(500 MHz, Chloroform-d) δ 7.89 (s, 1H), 7.83 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.2 Hz, 2H), 
7.28 (s, 1H), 7.12 – 7.05 (m, 3H), 6.82 (t, J = 7.2 Hz, 2H), 6.67 (t, J = 7.3 Hz, 1H), 6.48 (d, J
= 7.7 Hz, 2H), 4.54 (q, J = 6.8 Hz, 1H), 3.91 (br. s, 2H), 1.53 (d, J = 6.8 Hz, 3H). 13C NMR 
(126 MHz, Chloroform-d) δ 171.19, 149.77, 146.89, 140.73, 132.86(2), 129.17(2), 127.82, 
127.19, 126.24(2), 125.23(2), 124.56, 119.73, 118.34, 117.61, 113.33, 53.34, 25.05. HRMS: 
C21H22ON3, mass expected [M+H]
 + 332.17574, found 332.17548. 
4.1.17 N1-(2-aminophenyl)-N4-phenylterephthalamide (4c) 
The product was obtained using synthetic procedure 2. Yellow solid, yield 61%.1H NMR 
(500 MHz, DMSO-d6) δ 10.40 (s, 1H), 10.27 (s, 1H), 8.13 – 8.08 (m, 5H), 7.79 (d, J = 7.7 Hz, 
2H), 7.74 – 7.68 (m, 1H), 7.39 – 7.34 (dt, J = 10.0, 6.2 Hz, 4H), 7.13 (t, J = 7.2 Hz, 1H). 13C 
NMR (126 MHz, DMSO-d6) δ 165.21, 160.46, 139.42, 138.11, 137.27, 131.81, 129.13(2), 
128.32(2), 128.19, 128.14(2), 127.28, 126.67, 126.23, 126.53, 124.35, 120.96, 120.84. 
HRMS: C20H18O2N3, mass expected [M+H]
 + 332.13935, found 332.13913.  
 
4.1.18 N-(2-aminophenyl)-4-((methyl(phenyl)amino)methyl)benzamide (4d) 
The product was obtained using synthetic procedure 2. Yellow solid, yield 41%.1H NMR 
(500 MHz, DMSO-d6) δ 9.59 (s, 1H), 7.92 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.17 
– 7.13 (m, 3H), 6.98 – 6.94 (m, 1H), 6.79 – 6.75 (m, 1H), 6.72 (d, J = 8.1 Hz, 2H), 6.64 – 
6.57 (m, 2H), 4.88 (br. s, 2H), 4.64 (s, 2H), 3.05 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 
165.58, 149.37, 143.58, 143.35, 133.61, 129.46(2), 128.48, 128.40, 127.10, 127.04(2), 126.92, 
123.77, 116.50, 116.43, 112.61, 112.54, 99.98, 55.66, 39.23. HRMS: C21H22ON3, mass 
expected [M+H]+ 332.17574, found 332.17563. 
4.1.19 (R)- or (S)-N-(1-(4-bromophenyl)ethyl)aniline (7a,b) 
The product was obtained using synthetic procedure 4. Yellow solid, yield 32% - 33%.1H 
NMR (500 MHz, Chloroform-d) δ 7.50 – 7.34 (m, 2H), 7.26 – 7.23 (m, 2H), 7.11 – 7.07 (m, 
2H), 6.67 (t, J = 7.3 Hz, 1H), 6.48 (d, J = 7.9 Hz, 2H), 4.43 (q, J = 6.7 Hz, 1H), 1.50 (d, J = 
6.7 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 146.74, 144.20, 131.80, 131.73, 129.20, 
129.13, 127.69(2), 120.55, 117.68, 113.43(2), 53.25, 24.90. 













The product was obtained from (R)- or (S)-N-(1-(4-bromophenyl)ethyl)aniline using 
synthetic procedure 5. Yellow solid, yield 47% - 57%. 1H NMR (500 MHz, Chloroform-d) δ 
7.64 – 7.59 (m, 2H), 7.51 – 7.47 (m, 2H), 7.13 – 7.07 (m, 2H), 6.70 – 6.67 (m, 1H), 6.46 – 
6.42 (m, 2H), 4.51 (q, J = 6.8 Hz, 1H), 4.08 (br. s, 1H), 1.52 (d, J = 6.8 Hz, 3H). 13C NMR 
(126 MHz, Chloroform-d) δ 151.01, 146.55, 132.70(2), 129.26(2), 126.72(2), 118.93, 117.86, 
113.35(2), 110.79, 53.46, 24.97. 
4.1.21 (R)- or (S)-4-(1-(phenylamino)ethyl)benzoic acid (9a,b) 
The product was obtained from (R)- or (S)-4-(1-(phenylamino)ethyl)benzonitrile using 
synthetic procedure 6. Yellow solid, yield 57% - 97%. 1H NMR (500 MHz, Methanol-d4) δ 
8.03 (d, J = 8.1 Hz, 2H), 7.48 (m, 5H), 7.29 (d, J = 7.5 Hz, 2H), 4.90 (d, J = 6.2 Hz, 1H), 
1.79 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 165.85, 138.96, 132.68, 
130.22(2), 128.49, 128.41, 128.30, 127.67, 126.34(2), 121.42(2), 60.78, 16.01. 
4.1.22 (R)- or (S)-N-(2-aminophenyl)-4-(1-(phenylamino)ethyl)benzamide (10a,b) 
The product was obtained from (R)- or (S)-4-(1-(phenylamino)ethyl)benzoic acid using 
synthetic procedure 2. Yellow solid, yield 30% - 32%. The (S)-N-(2-aminophenyl)-4-(1-
(phenylamino)ethyl)benzamide [α]20D (c=1, CH2Cl2)= -8.6 ； (R)-N-(2-aminophenyl)-4-(1-
(phenylamino)ethyl)benzamide [α]20D(c=1, CH2Cl2)= +8.5 . 
4.1.23 6-(phenylamino)hexanoic acid (12a) 
The product was obtained using synthetic procedure 7. Yellow solid, yield 16%. 1H NMR 
(500 MHz, Chloroform-d) δ 7.19 – 7.16 (m, 2H), 6.71 (t, J = 7.3 Hz, 1H), 6.62 (d, J = 7.8 Hz, 
2H), 3.12 (d, J = 7.2 Hz, 2H), 2.38 (t, J = 7.4 Hz, 2H), 1.72 – 1.62 (m, 5H), 1.50 – 1.43 (m,
2H). 13C NMR (126 MHz, Chloroform-d) δ 179.16, 148.14, 129.26(2), 117.50 , 112.97(2), 
43.88, 33.87, 29.14, 26.59, 24.45. 
4.1.24 tert-butyl (2-(5-(phenylamino)pentanamido)phenyl)carbamate (14a) 
The product was obtained using synthetic procedure 2. Yellow solid, yield 46%. 1H NMR 
(500 MHz, Chloroform-d) δ 8.02 (br. s, 1H), 7.55 – 7.51 (m, 1H), 7.39 (d, J = 8.7 Hz, 1H), 
7.33 (q, J = 5.0 Hz, 1H), 7.19 – 7.14 (m, 3H), 6.74 (br. s, 1H), 6.69 (t, J = 7.3 Hz, 1H), 6.59 
(d, J = 7.9 Hz, 1H), 6.37 (d, J = 8.7 Hz, 1H), 3.15 – 3.08 (m, 2H), 2.42 – 2.39 (m, 2H), 1.82 – 
1.71 (m, 2H), 1.69 – 1.63 (m, 2H), 1.52 – 1.48 (m, 11H).13C NMR (126 MHz, Chloroform-d) 
δ 204.06, 171.86, 148.37, 130.36, 129.25(2), 126.18, 125.74, 124.52, 121.59, 117.20(2), 
112.72(2), 81.11, 43.72, 37.27, 29.24, 28.30(3), 26.71, 25.45. 













The product was obtained using synthetic procedure 2. Yellow solid, yield 66%.  1H NMR 
(500 MHz, Chloroform-d) δ 8.30 (br. s, 1H), 7.97 – 7.92 (m, 2H), 7.59 – 7.55 (m, 1H), 7.47 – 
7.40 (m, 4H), 7.16 – 7.10 (m, 1H), 7.08 (br. s, 1H), 2.99 (t, J = 7.3 Hz, 2H), 2.38 (t, J = 7.5 
Hz, 2H), 1.80 – 1.74 (m, 4H), 1.49 (s, 9H), 1.47 – 1.41 (m, 2H). 13C NMR (126 MHz, 
Chloroform-d) δ 200.39, 172.25, 154.22, 136.92, 133.05, 130.79, 130.06, 128.61(2), 
128.04(2), 126.14, 125.35, 124.53(2), 80.83, 38.28, 36.95, 28.75, 28.32(3), 25.50, 23.75. 
4.1.26 tert-butyl (2-(5-oxo-5-(phenylamino)pentanamido)phenyl)carbamate(14c) 
The product was obtained using synthetic procedure 2. Yellow solid, yield 66%. 1H NMR 
(500 MHz, Chloroform-d) δ 8.49 (br. s, 1H), 7.80 – 7.77 (m, 2H), 7.50 – 7.37 (m, 5H), 7.18 – 
7.07 (m, 3H), 6.67 (br. s, 1H), 3.46 (q, J = 6.5 Hz, 2H), 2.44 (t, J = 7.1 Hz, 2H), 1.82 – 1.76 
(m, 2H), 1.71 – 1.65 (m, 2H), 1.48 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 172.70, 
168.22, 154.57, 134.80, 131.87, 131.17, 130.29, 128.95, 127.33(2), 126.57, 125.67, 125.54(2), 
124.91, 81.25, 39.59, 36.58, 29.19, 28.68(3), 23.01. 
4.1.27 N-(2-aminophenyl)-5-(phenylamino)pentanamide(15a) 
The product was obtained using synthetic procedure 8. Yellow solid, yield 90%.1H NMR 
(500 MHz, DMSO-d6) δ 9.10 (s, 1H), 7.15 (d, J = 8.8 Hz, 1H), 7.04 (t, J = 7.8 Hz, 2H), 6.88 
(t, J = 8.2 Hz, 1H), 6.71 (d, J = 9.0 Hz, 1H), 6.54 – 6.47 (m, 4H), 5.51 (t, J = 5.6 Hz, 1H), 
4.81 (s, 2H), 2.98 (q, J = 6.8 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 1.66 – 1.54 (m, 4H), 1.44 – 
1.38 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 171.55, 148.36, 140.75, 129.27(2), 
127.24, 125.17, 124.36, 119.66, 118.35, 117.23, 112.74( ), 43.68, 36.88, 29.22, 26.74, 25.51. 
 
4.1.28 N-(2-aminophenyl)-6-oxo-6-phenylhexanamide(15b) 
The product was obtained using synthetic procedure 8. Yellow solid, yield 96%. 1H NMR 
(500 MHz, DMSO-d6) δ 9.09 (s, 1H), 7.97 (d, J = 7.1 Hz, 2H), 7.63 (t, J = 7.4 Hz, 1H), 7.52 
(t, J = 7.7 Hz, 2H), 7.14 (d, J = 9.1 Hz, 1H), 6.88 (t, J = 8.3 Hz, 1H), 6.70 (d, J = 9.2 Hz, 1H), 
6.52 (t, J = 8.2 Hz, 1H), 4.81 (br. s, 2H), 3.04 (t, J = 7.2 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 
1.73 – 1.57 (m, 4H), 1.31 – 1.35 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 200.56, 171.56, 
142.36, 137.19, 133.50, 129.87, 129.22(2), 128.33(2), 126.14, 125.78, 124.00, 116.27, 38.28, 
36.12, 28.77, 25.67, 24.05.  
4.1.29 N-(5-((2-aminophenyl)amino)-5-oxopentyl)benzamide(15c) 
The product was obtained using synthetic procedure 8. Yellow solid, yield 72%. 1H NMR 













(t, J = 7.3 Hz, 1H), 7.45 (t, J = 7.4 Hz, 2H), 7.15 (d, J = 7.7 Hz, 1H), 6.88 (t, J = 7.6 Hz, 1H), 
6.70 (d, J = 7.9 Hz, 1H), 6.52 (t, J = 7.5 Hz, 1H), 4.83 (s, 2H), 3.29 (q, J = 6.3 Hz, 2H), 2.35 
(t, J = 7.2 Hz, 2H), 1.67 – 1.54 (m, 4H). 13C NMR (126 MHz, DMSO-d6) δ 171.52, 166.56, 
142.35, 135.15, 131.51, 128.70(2), 127.68, 127.54, 125.76, 126.18(2), 123.98, 116.30, 39.52, 
35.94, 29.31, 23.37. 
4.2 HDAC inhibition study 
Black 96-well flat bottom microplates (Corning® Costar®, Corning Incorporated, NY) were 
used. Human recombinant C-terminal FLAG-tag, C-terminal His-tag HDAC 1 (BPS 
Bioscience, Catalog #: 50051), human recombinant C-terminal FLAG-tag HDAC 2 (BPS 
Bioscience, Catalog #: 50052) or human recombinant C-terminal His-tag HDAC 3/NcoR2 
(BPS Bioscience, Catalog #: 50003) were diluted in incubation buffer (25 mM Tris-HCl, pH 
8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl, 0.01% Triton-X and 1 mg/mL BSA). 40 µL 
of this dilution was incubated with 10 µL of different concentrations of inhibitors in 10% 
DMSO/incubation buffer and 50 µL of the fluorogenic Boc-Lys(ε-Ac)-AMC (20 mM, 
Bachem, Germany) at 37 °C. After 90 min incubation time 50 µL of the stop solution (25 
mM Tris-HCl (pH 8), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.01% Triton-X, 6.0 
mg/mL trypsin (porcine pancreas Type IX-S, lyophilized powder, 13,000-20,000 BAEE 
units/mg protein, Sigma Aldrich) and 200 µM vorinostat) was added. After a following 
incubation at 37 °C for 30 min, the fluorescence was measured on a Synergy H1 Platereader 
(BioTek, USA) with a gain of 70 and an excitation wavelength of 370 nm and an emission 
wavelength of 460 nm. GraphPad Prism 5.0 (GraphPad Software, Inc.) was used for the 
determination of the IC50 of each inhibitor. Nonlinear regression was used for data fitting. 
4.3 Docking study 
Docking studies where performed to get insight in the structure activity relationships. All 
molecular handlings were done with the program Discovery studio (Dassault systèmes) 
version 2018 and the crystal structures of human HDAC 1 (PDB-code:5ICN), human HDAC 
2 (PDB-code: 4LY1) and human HDAC 3 (PDB-code: 4A69). 
The CDOCKER protocol was used for docking which is a CHARMm based algorithm. 
Docking was verified by use of the ligand (4-(acetylamino)-N-[2-amino-5-(thiophen-2-
yl)phenyl]benzamide) from de crystal structure 4LY1. This ligand contains the zinc-binding 
group and the linker group also present in our molecules. First, the ligand was removed from 
4LY1 and subsequently docked back in the crystal structure. All 10 poses given show a 













Also the ligand was placed in HDAC 1 and HDAC 3 after superimposing HDAC 1 and 
HDAC 3 with HDAC 2 at the Cα carbon atoms of the backbone. The position of the o-
aminoanilide core was used as a reference to evaluate the dockings in the HDAC active sites. 
Docked poses from all the compounds where the NH2 from the zinc-binding group did not 
face the zinc in the same fashion as the reference, were discarded. Poses with the lowest 
CDOCKER energies were chosen.  
4.4 Cell viability 
4.4.1 Cell culture 
RAW264.7 macrophages were obtained from the American Type Culture Collection 
(ATCC; Wesel, Germany) and cultured in 96-well plate or flasks (Costar Europe, 
Badhoevedrop, The Netherlands) at 37 oC under 5% CO2/95% air in Dulbecco’s Modification 
of Eagle’s Medium (DMEM) containing GlutaMAX™ (Gibco® by life Technologies, 
Bleiswijk, The Netherlands) supplemented with 10% (v/v) heated fetal bovine serum (FBS; 
Invitrogen, Breda, The Netherlands), 2 mM additional GlutaMAX™ (Gibco® by life 
Technology, Bleiswijk, The Netherlands), 100 U/ml penicillin (Gibco® by life Technologies, 
Bleiswijk, The Netherlands) and 100 µg/ml streptomycin (Gibco® by life Technologies, 
Bleiswijk, The Netherlands). RAW 264.7 cells were used between passage 5 and 16. 
4.4.2 MTS assay 
RAW264.7 cells were seeded in 96-well plate at the concentration of 25,000 cells/cm2. 
The next day, medium was replaced with fresh medium containing HDAC inhibitors at the 
indicated concentrations. After 24 h incubation at 37 oC, 20 µl CellTiter 96 AQueous One 
Solution reagent (Promega) was added to each well. The cells were incubated at 37 oC for 2 h 
in dark. The absorbance at 490 nM was measured using an Synergy H1 plate reader. The 
results were plotted as % of control. 
4.5  NF-κB activation 
RAW-Blue™ cells (InvivoGen, San Diego, CA, USA) are derived from RAW264.7 
macrophages. The secreted embryonic alkanline phosphatase (SEAP) is detected using SEAP 
detection medium (QUANTI-Blue™). RAW-Blue cells were seeded at a concentration 
around 550,000 cells/mL. The cells were treated with 10 ng/mL LPS/IFNγ for 4 h, after the 
pre-incubation with HDAC inhibitors for 16 h. The dtection medium (QUANTI-BLUE) was 
prepared according to the manufacturer’s protocol. 20 µl cell supernatant was added into 180 













a Synergy H1 plate reader with absorbance at 650 nm. The results were plotted as % of 
control. RAW-Blue cells were used between passage 4 to 1 . 
4.6  RT-qPCR 
RAW264.7 cells were washed twice with Dulbecco’s Phosphate-buffered Saline (DPBS, 
Gibco® by life Technologies, Bleiswijk, The Netherlands) and total RNA was isolated by 
Maxwell® 16 LEV simplyRNA Tissue Kit (Promega) according to the manufacturer’s 
protocol. RNA concentration(OD260) and purity (OD260/OD280) were measured by 
NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA). Then, RNA was reverse transcribed to cDNA using the Reverse Transcription Kit 
(#A3500, Promega). 10 ng of cDNA, 5 µL 2x SensiMix SYBR Lo-ROX and 0.4 µL  primers 
were applied for each RT-qPCR, which was performed on a QuantStudio(TM) 7 Flex System. 
For each sample, the real-time PCR were performed in duplicate. Data analysis was 
performed with QuantStudio™ Real-Time PCR Software. Gene expression levels were 
normalized to the expression of the reference gene glyceralde-3-phosphate dehydrogenase 
(GAPDH), which was not influenced by the experimental conditions resulting in the ∆Ct 
value. Gene expression levels were calculated by the comparative Ct method (2
-∆∆Ct)[28].  
Primers for qRT-PCR were as follows: 
GAPDH forward, 5’- ACAGTCCATGCCATCACTGC-3’;  
GAPDH reverse, 5’- GATCCACGACGGACACATTG-3’; 
IL-10 forward, 5’- ATAACTGCACCCACTTCCCAGTC-3’;  
IL-10 reverse, 5’- CCCAAGTAACCCTTAAAGTCCTGC-3’; 
IL-6 forward, 5’- TGATGCTGGTGACAACCACGGC-3’;  
IL-6 reverse, 5’- TAAGCCTCCGACTTGTGAAGTGGTA-3’; 
TNFα forward, 5’- CATCTTCTCAAAATTCGAGTGACAA-3’;  
TNFα reverse, 5’- GAGTAGACAAGGTACAACCC-3’; 
miNOS forward, 5’- CTATCAGGAAGAAATGCAGGAGAT-3’;  
miNOS reverse, 5’- GAGCACGCTGAGTACCTCATT-3’; 
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• Selectivity among HDAC 1, 2 and 3 was correlated to inflammation. 
• A positional difference in a conserved amino acid explains inhibitory 
selectivity among HDAC 1 and 3. 
• HDAC 1 and/or HDAC 2 selectivity increased the NF-κB activity, and pro-
inflammatory gene transcription.  
• Small molecule HDAC 3 inhibition had not effect in NF-κB activity and pro-
inflammatory gene transcription. 
